Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 20, 2025 16:05 ET | Source: Lexeo Therapeutics

Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares in the Public Offering

Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters’ Option
October 16, 2025 23:29 ET | Source: Lexeo Therapeutics

Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement

Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement
October 16, 2025 16:32 ET | Source: Lexeo Therapeutics

Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants
October 07, 2025 06:00 ET | Source: Lexeo Therapeutics

Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy

Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval and Positive Interim Clinical Data for LX2006 in FA Cardiomyopathy
August 14, 2025 07:30 ET | Source: Lexeo Therapeutics

Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights

Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights
July 07, 2025 07:00 ET | Source: Lexeo Therapeutics

Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia

Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia
June 24, 2025 07:30 ET | Source: Lexeo Therapeutics

Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics

Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics
May 27, 2025 07:31 ET | Source: Lexeo Therapeutics

Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases

Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases
May 12, 2025 07:00 ET | Source: Lexeo Therapeutics

Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights

Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights
May 01, 2025 09:16 ET | Source: Lexeo Therapeutics

Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting